The Daily Biotech Pulse: Progenics Posts Mixed Trial Results,...


Vital Therapies Inc Progenics Pharmaceuticals, Inc. released top-line data from its Phase 3 trial of 1404, a prostate-specific membrane antigen-targeted small molecule SPECT/CT imaging agent designed to visualize prostate cancer. The study showed that 1404 detected clinically meaningful prostate cancer with specificity ranging among the three readers from 71-75 percent.



from Biotech News